Phase 2 trial of NTC-942 in patients with mild cognitive impairment

Trial Profile

Phase 2 trial of NTC-942 in patients with mild cognitive impairment

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs PRX 3140 (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Sponsors Ology Bioservices
  • Most Recent Events

    • 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
    • 22 Feb 2016 According to Nanotherapeutics website (http://www.nanotherapeutics.com/prx-3140/), company has plan to initiate this trial by late 2015 with completion set in 2016.
    • 22 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top